[Nicotine, alcohol and opioids - three interacting substances]

Area of Science:

• Addiction Medicine
• Neuroscience
• Public Health

Background:

• Nicotine and alcohol co-use is prevalent, increasing disease burden and dependence risk.
• Alcohol dependence is associated with higher smoking rates and reduced nicotine cessation success.
• Interactions between nicotine and opioids contribute to dependence and complicate pain management.

Purpose of the Study:

• To examine the intricate relationship between nicotine, alcohol, and opioid use.
• To highlight the public health implications of co-occurring substance use disorders.
• To identify urgent research needs concerning nicotine-opioid interactions.

Main Methods:

• Review of existing literature on substance use interactions.
• Analysis of epidemiological data on co-use prevalence.
• Examination of neurobiological mechanisms underlying cross-tolerance.

Main Results:

• Nicotine users face higher risks of alcohol dependence; alcohol consumption is common during adolescent tobacco experimentation.
• Individuals with alcohol dependence exhibit higher smoking prevalence and experience more severe nicotine withdrawal, hindering cessation.
• Combined alcohol and smoking significantly elevates disease burden, with smoking-related illnesses causing more deaths in alcohol-dependent individuals.
• Nicotine cessation interventions are more effective when integrated with alcohol use advice.
• Cross-tolerance and interactions between nicotine and opioids heighten dependence risks, necessitating higher opioid doses for pain relief in smokers.
• Smoking is linked to increased opioid dependence risk, with nicotine as a key factor, though causality requires further investigation.

Conclusions:

• Integrated treatment of nicotine dependence within opioid dependence management shows promise.
• Further human research is critical to elucidate nicotine-opioid interactions and optimize treatment timing.
• Addressing co-occurring nicotine and alcohol use is essential for reducing overall disease burden and improving cessation outcomes.